# KN026

Source: https://onco.cc/drugs/kn026/  
OnCo record `kn026` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KN026 is an experimental monoclonal antibody from Shanghai JMT-Bio in phase 3 trials for HER2-positive breast cancer and HR-positive / HER2-negative breast cancer, aimed at HER2.

## Summary

KN026 is a monoclonal antibody developed by Shanghai JMT-Bio and CSPC Megalith Biopharmaceutical. Its target is HER2. ClinicalTrials.gov describes the intervention as: KN026 is an antibody targeting HER2, administered via intravenous infusion. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07441460 (A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer) and NCT06747338 (A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer), in HER2-positive breast cancer and HR-positive / HER2-negative breast cancer. The largest, NCT07441460, plans to enrol 1800 participants with primary completion expected 2034-08-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at HER2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of KN026: https://clinicaltrials.gov/search?intr=KN026

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)
- trials: [A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer](https://onco.cc/trials/nct07597629/), [A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer](https://onco.cc/trials/nct06747338/), [A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer](https://onco.cc/trials/nct07441460/)

---
JSON: https://onco.cc/api/v1/entities/kn026.json